Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility

The steroid 11beta-hydroxylase inhibitor metyrapone is able to effectively reverse the hypercortisolemia detected in human Cushing’s Syndrome patients. In this current preclinical study, we investigated whether metyrapone monotherapy can also reverse the hypercortisolemia-associated increase in athe...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Sluis, Ronald J., van den Aardweg, Tim, Sijsenaar, Timothy J. P., Van Eck, Miranda, Hoekstra, Menno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526766/
https://www.ncbi.nlm.nih.gov/pubmed/37759687
http://dx.doi.org/10.3390/biom13091287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526766/
https://www.ncbi.nlm.nih.gov/pubmed/37759687
http://dx.doi.org/10.3390/biom13091287

Ejemplares similares